CN113913322A - 乳双歧杆菌BLa80在缓解腹泻和提升肠道免疫能力中的应用 - Google Patents
乳双歧杆菌BLa80在缓解腹泻和提升肠道免疫能力中的应用 Download PDFInfo
- Publication number
- CN113913322A CN113913322A CN202110978637.8A CN202110978637A CN113913322A CN 113913322 A CN113913322 A CN 113913322A CN 202110978637 A CN202110978637 A CN 202110978637A CN 113913322 A CN113913322 A CN 113913322A
- Authority
- CN
- China
- Prior art keywords
- bifidobacterium lactis
- bla80
- product
- diarrhea
- bifidobacterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 title claims abstract description 75
- 229940009289 bifidobacterium lactis Drugs 0.000 title claims abstract description 74
- 206010012735 Diarrhoea Diseases 0.000 title claims abstract description 31
- 230000008944 intestinal immunity Effects 0.000 title claims abstract description 13
- 241000588724 Escherichia coli Species 0.000 claims abstract description 15
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 14
- 241000607142 Salmonella Species 0.000 claims abstract description 13
- 230000003385 bacteriostatic effect Effects 0.000 claims abstract description 5
- 238000004321 preservation Methods 0.000 claims abstract 7
- 239000003814 drug Substances 0.000 claims description 8
- 235000013305 food Nutrition 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 239000002068 microbial inoculum Substances 0.000 claims 2
- 241000699670 Mus sp. Species 0.000 abstract description 24
- 238000007334 copolymerization reaction Methods 0.000 abstract description 9
- 241000894006 Bacteria Species 0.000 abstract description 6
- 210000002490 intestinal epithelial cell Anatomy 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 244000005700 microbiome Species 0.000 abstract description 2
- 244000052616 bacterial pathogen Species 0.000 description 18
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 15
- 230000001580 bacterial effect Effects 0.000 description 15
- 239000006041 probiotic Substances 0.000 description 14
- 235000018291 probiotics Nutrition 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000000725 suspension Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000000529 probiotic effect Effects 0.000 description 10
- 210000001072 colon Anatomy 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 239000007788 liquid Substances 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 5
- 230000003042 antagnostic effect Effects 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000186000 Bifidobacterium Species 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 3
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 208000035861 hematochezia Diseases 0.000 description 3
- 235000020256 human milk Nutrition 0.000 description 3
- 210000004251 human milk Anatomy 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- YLZYSVYZMDJYOT-UHFFFAOYSA-N 2-methoxypyrimidine Chemical compound COC1=NC=CC=N1 YLZYSVYZMDJYOT-UHFFFAOYSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 241001134770 Bifidobacterium animalis Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960004099 azithromycin Drugs 0.000 description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 2
- 229940118852 bifidobacterium animalis Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229960005361 cefaclor Drugs 0.000 description 2
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 2
- 229960004755 ceftriaxone Drugs 0.000 description 2
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 2
- 229960001019 oxacillin Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000019637 Infantile Diarrhea Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- -1 cephamine Chemical compound 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- XFIKMPRBSORKQP-JATHGWPISA-M lithium;9-[(e)-4-[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s,3s)-3-[(2s,3s)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoate Chemical class [Li+].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 XFIKMPRBSORKQP-JATHGWPISA-M 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960002950 novobiocin Drugs 0.000 description 1
- YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/515—Animalis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了乳双歧杆菌BLa80在缓解腹泻和提升肠道免疫能力中的应用,属于微生物技术领域。本发明的乳双歧杆菌BLa80保藏编号为CGMCC No.22547,其对大肠杆菌、沙门氏菌和金黄色葡萄球菌有很强的抑菌能力和共聚能力,对肠道上皮细胞具有较强的黏附能力,能够改善实验小鼠的腹泻发生率和提升实验小鼠的肠道免疫力。本发明的乳双歧杆菌BLa80可用于制备抑菌、预防和/或缓解腹泻、提升肠道免疫能力的产品,市场价值高。
Description
技术领域
本发明属于微生物技术领域,尤其涉及一种乳双歧杆菌BLa80在缓解腹泻和提升肠道免疫能力中的新应用。
背景技术
腹泻是人体最常见的消化系统疾病,引起腹泻的病原体主要包括大肠杆菌、沙门氏菌和金黄色葡萄球菌等。益生菌是肠道菌群中的优势菌群,其中双歧杆菌和乳杆菌是肠道中典型的益生菌。已有研究表明,益生菌的有益作用是可以黏附在肠黏膜上,抑制病原菌对肠粘膜的黏附作用,抑制有害菌的生长,稳定微生物群落结构,从而预防消化道炎症疾病发生,防止腹泻,比如婴儿腹泻、急性腹泻、旅行者腹泻、抗生素相关腹泻以及轮状病毒引起的腹泻等,还能降低血清中的胆固醇,刺激免疫系统以及提升肠道的免疫能力。
发明内容
本发明的目的在于提供一种乳双歧杆菌BLa80的新应用。
所述的乳双歧杆菌BLa80来源于母乳,该菌株于2021年05月17日保藏于中国微生物菌种保藏管理委员会普通微生物中心(CGMCC),地址:北京市朝阳区北辰西路1号院3号,该菌株分类命名为动物双歧杆菌乳亚种(Bifidobacterium animalis subsp.lactis),保藏编号为CGMCC No.22547。乳双歧杆菌BLa80能够耐受胃肠道环境,具有较强耐胃酸耐肠液能力;对15种常见抗生素红霉素、青霉素、阿莫西林、氨苄西林、万古霉素、头孢克洛、苯唑西林、头孢曲松、新生霉素、新霉素、头孢噻吩、克林霉素、阿奇霉素、甲氧嘧啶和利福平均敏感,无抗生素耐性,安全性高;对大肠杆菌、沙门氏菌和金黄色葡萄球菌等病原菌均具有极强的抑菌能力。
进一步研究发现,乳双歧杆菌BLa80对大肠杆菌、沙门氏菌和金黄色葡萄球菌有很强的共聚能力,病原菌大肠杆菌、鼠寒沙门氏菌和金黄色葡萄球菌均为常见引起腹泻的病原菌,比如季节性腹泻和旅行相关性腹泻。乳双歧杆菌BLa80具有较强的黏附能力,能与肠道上皮细胞发生黏附,发挥其益生作用。乳双歧杆菌BLa80能显著改善实验小鼠的腹泻发生率,能够提升实验小鼠肠道免疫力,降低实验小鼠结肠组织中促炎因子的表达,提高抗炎因子的表达。
基于上述内容,本发明提供如下应用和产品:
一种上述乳双歧杆菌BLa80在制备抑菌产品中的应用,所述的抑菌包括抑制大肠杆菌、沙门氏菌和金黄色葡萄球菌等。
一种上述乳双歧杆菌BLa80在制备预防和/或缓解腹泻产品中的应用。
一种上述乳双歧杆菌BLa80在制备提升肠道免疫能力产品中的应用。
一种抑菌产品,含有上述乳双歧杆菌BLa80。所述的抑菌包括抑制大肠杆菌、沙门氏菌和金黄色葡萄球菌等。
一种用于预防和/或治疗腹泻的产品,含有上述乳双歧杆菌BLa80。
一种用于提升肠道免疫能力的产品,含有上述乳双歧杆菌BLa80。
上述产品是一种包含乳双歧杆菌BLa80的功能性菌剂、食品、保健品和/或药品。
本发明的有益效果在于:本发明提供乳双歧杆菌BLa80的新用途,该菌种在预防和/或缓解腹泻以及在提升肠道免疫力产品中的应用。BLa80的特点是分离来源于母乳,安全性高,具有较强的耐受能力,较强的拮抗病原菌的能力,以及与不同病原菌的共聚能力,较强的黏附能力,并与肠道上皮细胞发生黏附,发挥其益生作用,市场价值高。
附图说明
图1是乳双歧杆菌BLa80对不同病原菌的拮抗能力结果图。
图2是乳双歧杆菌BLa80与不同病原菌的共聚能力结果图。
图3是不同组小鼠的腹泻率。
图4是不同组小鼠结肠组织中TNF-α的含量。
图5是不同组小鼠结肠组织中IL-6的含量。
图6是不同组小鼠结肠组织中IL-4的含量。
图7是不同组小鼠结肠组织中IL-10的含量。
具体实施方式
下面结合实施例对本发明做进一步详细的描述,但本发明的实施方式不限于此。
实施例1乳双歧杆菌BLa80分离、筛选和鉴定
(1)分离与筛选:
采集中国边远牧区的母乳样品,无菌生理盐水稀释至合适梯度,涂布于添加有5%(V/V)的莫匹罗星锂盐、且含有0.1%的L-半胱氨酸盐酸盐的MRS琼脂平板上,37℃厌氧条件下培养48h。挑选不透明乳白色、圆形有光泽、边缘整齐、表面凸起且湿润的单克隆菌落,在MRS固体培养基上进行反复划线纯化培养,经过细胞形态和个体形态观察,获得双歧杆菌菌株。
(2)分子生物学鉴定:
将双歧杆菌菌株采用基因组DNA抽提试剂盒提取菌株基因组DNA,采用上游引物27F(AGTTTGATCMTGGCTCAG)和下游引物1492R(GGTTACCTTGTTACGACTT),对16S rDNA序列进行扩增,得到PCR产物。并对PCR产物进行测序。其中PCR反应体系:10×Buffer20μL,引物dNTP 4μL,上、下游引物各1μL,DNA模板2μL,Taq酶0.5μL,ddH2O 34.5μL。PCR反应条件:95℃10min;94℃30s,56℃30s,72℃2min,35个循环;72℃10min。将PCR产物通过凝胶电泳检测后送往武汉金开瑞生物工程有限公司测序。将鉴定的基因序列提交至NCBI数据库(www.ncbi.nlm.nih.gov)中进行BLAST分析比对。根据分子生物学的鉴定结果,确定该菌株为乳双歧杆菌,将其命名为乳双歧杆菌BLa80。乳双歧杆菌BLa80的16S rDNA序列如SEQ IDNo 1所示。
乳双歧杆菌BLa80于2021年05月17日保藏于中国微生物菌种保藏管理委员会普通微生物中心(CGMCC),地址:北京市朝阳区北辰西路1号院3号,该菌株分类命名为动物双歧杆菌乳亚种(Bifidobacterium animalis subsp.lactis),保藏编号为CGMCC No.22547。
实施例2乳双歧杆菌BLa80通过胃肠道的环境评价
模拟人工胃液:配制0.5%NaCl溶液,加入0.3%胃蛋白酶,用1mol/L HCL调节pH值至2.5,然后充分溶解后用0.22μm微孔滤膜过滤除菌备用。
模拟人工肠液:配制0.5%NaCl溶液,加入0.1%胰蛋白酶,用0.1mol/L NaOH调节pH值至8.0,然后充分溶解后用0.22μm微孔滤膜过滤除菌备用。
乳双歧杆菌BLa80在厌氧条件下活化培养2代。将活化后的乳双歧杆菌BLa80菌液离心,收集菌体。取0.4mL菌体悬液分别接入1.6mL配制好的pH2.5的模拟人工胃液和pH8.0的模拟人工肠液中混匀,37℃条件下消化,同时分别取0h和3h的消化液检测活菌数,计算存活率,结果见表3。其中,菌株存活率(%)=Nt/N0×100%,式中N0表示菌株0h的活菌数(CFU/mL),Nt表示菌株3h的活菌数(CFU/mL)。
表1乳双歧杆菌BLa80模拟消化道环境实验数据表
表1结果显示,乳双歧杆菌Bla80在pH2.5的人工胃液中3h存活率为96.7%,在pH8.0的人工肠液中3h存活率为93.6%。实验说明,该乳双歧杆菌BLa80具备较强的耐受胃肠道环境的能力。
实施例3乳双歧杆菌BLa80的抗生素敏感性评价
将待测菌在含有0.1%的L-半胱氨酸盐酸盐的MRS固体平板上划线活化后,制备菌悬液并调整菌悬液浓度为108CFU/mL,取100μL菌悬液加入含有0.1%的L-半胱氨酸盐酸盐MRS固体平板上,用无菌棉签将菌液均匀涂布在平板上,贴上抗生素药敏片,以无抗生素的纸片为空白对照。置于厌氧条件下,37℃正置培养,24h后用直尺测量菌株对抗生素敏感性直径,结果见表2。
表2乳双歧杆菌BLa80对抗生素敏感性数据(mm)
表2结果所示,乳双歧杆菌BLa80对评价的14种抗生素红霉素、青霉素、阿莫西林、氨苄西林、万古霉素、头孢克洛、苯唑西林、头孢曲松、新生霉素、头炮噻吩、克林霉素、阿奇霉素利福平和甲氧嘧啶是高度敏感,抑菌圈直径都大于20mm,其中有10种抗生素的抑菌圈直径大于30mm。实验说明,乳双歧杆菌BLa80是安全的益生菌。
实施例4乳双歧杆菌BLa80的抑菌活性评价
取拮抗菌株按2%(V/V)接种至含有0.1%的L-半胱氨酸盐酸盐MRS液体培养基的厌氧玻璃管中,37℃恒温静置培养12h。将致病菌株大肠杆菌、沙门氏菌、金黄色葡萄球菌分别接种于液体牛肉膏蛋白胨培养基中,37℃、转数250rpm、恒温摇床过夜培养,然后制备病原菌悬液。将MRS固体培养基冷却至55℃左右,与病原菌悬液按一定比例混匀,使体系病原菌活菌数在106CFU/mL数量级,然后迅速倾注于预先放置牛津杯的平板中,待培养基冷却凝固后,取出牛津杯,于每孔注入200μL拮抗菌株菌液,将平皿轻盖后正置于37℃恒温培养箱,培养适宜时间后观察,并用游标卡尺测量抑菌圈直径。
结果如图1显示,乳双歧杆菌BLa80对大肠杆菌、伤寒沙门氏菌和金黄色葡萄球菌拮抗直径分别是42mm、41mm、27mm。表现出对肠道致病菌极强的抑制作用,尤其对大肠杆菌和沙门氏菌的抑制能力。
实施例5乳双歧杆菌BLa80与大肠杆菌、沙门氏菌和金黄色葡萄球菌的共聚能力
乳双歧杆菌在厌氧条件下活化培养2代。将活化后的乳双歧杆菌BLa80菌液离心,收集菌体,PBS缓冲液清洗菌体2次后,然后重悬,调整OD600在0.6左右。病原菌大肠杆菌、金黄色葡萄球菌、沙门氏菌分别活化后,离心,收集菌体,PBS缓冲液清洗菌体2次后,然后重悬,调整OD600在0.6左右。取4mL乳双歧杆菌与4mL病原菌等体积混合,涡旋,充分混匀,室温静置孵育24h后,分别吸取上清测定菌液OD600。观察乳双歧杆菌与三种病原菌在24h时的共聚能力。同时以菌株L.lactis Bb-12作为对照,该菌株是公认的具有多种益生功能的商业菌株。
共聚力计算方式:
共聚力(%)=[(Ax+Ay)/2-A(x+y)]/[(Ax+Ay)/2]×100%
其Ax代表乳双歧杆菌初始OD600,Ay代表病原菌的初始OD600,A(x+y)代表混合后在不同测定时间的OD600。
由图2可知,与菌株L.lactis Bb-12相比较,乳双歧杆菌BLa80有较强的与大肠杆菌、沙门氏菌和金黄色葡萄球菌的共聚能力。益生菌与病原菌的共聚能力越强,更能有效阻止病原菌黏附并定植于肠黏膜上,说明越有利于人体健康。
实施例6乳双歧杆菌BLa80的黏附能力测试
菌种活化:乳双歧杆菌BLa80按2%接种量接种于含有0.1%的L-半胱氨酸盐酸盐MRS液体培养基的厌氧玻璃管中,37℃培养14h,取发酵液离心、收集菌体,用PBS洗涤3次后,将菌体重悬于不含双抗的DMEM培养液中,调节菌悬液的浓度为108CFU/mL。
HT-29细胞培养:在细胞培养瓶中,加入5mL DMEM完全培养液(含10%胎牛血清,1%青霉素和链霉素溶液),于5%CO2恒温培养箱中37℃孵育,每天换1次培养液,待细胞状态良好后(70%~80%融合),用0.2%消化液(胰酶-EDTA)进行消化传代。
黏附性试验:将消化的HT-29细胞调整浓度到105cell/mL,接种到12孔细胞培养板中,每孔1mL,于5%CO2浓度的培养箱中孵育至细胞长至单层,用无菌PBS洗涤两次,其中1孔用胰酶消化,用血球计数板进行细胞计数;分别2孔加入BLa80菌悬液和对照菌鼠李糖乳杆菌LGG菌悬液各1mL,于5%CO2培养箱中37℃孵育2h后,用无菌PBS洗涤细胞5次,除去未黏附的菌悬液,每孔加入0.2mL胰酶-EDTA缓冲液消化细胞5min,消化完后加入0.8mL PBS吹打均匀,取菌液进行稀释活菌计数。上述细胞黏附性实验以鼠李糖乳杆菌LGG作为对比菌株,每个实验做3个平行,鼠李糖乳杆菌LGG是行业内公认的黏附性较好的商业菌株,通过黏附实验对菌株对HT-29细胞的黏附性进行检测,结果如表3。
表3乳双歧杆菌BLa80黏附特性测试结果
由表3结果可知,本发明的乳双歧杆菌BLa80菌株黏附性能有明显优势。
实施例7BLa80对BALB/c雄性小鼠无毒副作用
将乳双歧杆菌BLa80菌体重悬于PBS溶液中,制成浓度为2.0×109CFU/mL的菌悬液。取体重20g左右的健康雄性BALB/c小鼠10只,适应环境5天后,每日给予20mL/kg bw进行灌胃,观察一周,记录死亡和体重情况。
实验结果表明,乳双歧杆菌BLa80未对小鼠造成明显影响,体重无显著变化,无死亡现象产生。小鼠外观无明显病理症状。
实施例8乳双歧功能BLa80缓解小鼠腹泻的作用
实验取SPF级BALB/c雄性小鼠36只,体重18-20g。动物饲养室温温度23±2℃,湿度50%±10%,12h/12h昼夜交替,自由进食及饮水的条件下适应饲养5天后随机分组,每组12只,分为3组,包括对照组、模型组(葡聚糖硫酸钠DSS)和益生菌+DSS组(灌胃乳双歧杆菌BLa80菌液,同时饮用DSS),试验期14天。对照组,试验开始到结束期间每天自由进食和饮水;模型组,前7天自由进食和饮水,第8天开始在小鼠饮水中添加2.5%(W/V)DSS溶液;益生菌+DSS组:前7天每天灌胃含2.0×109CFU/mL乳双歧杆菌BLa80的PBS溶液0.2mL;从第8天开始,灌胃含2.0×109CFU/mL乳双歧杆菌BLa80的PBS溶液0.2mL,同时小鼠饮水中添加2.5%DSS溶液。每天观察各组小鼠的粪便性状、便血和腹泻情况,并统计腹泻率。
结果(图3)显示,模型组(DSS)给药第3天,个别出现肉眼可见便血症状,第4天出现小鼠腹泻现象,给药7天后,小鼠腹泻症状(包括稀疏粪便)有56%。益生菌+DSS组给药第4天个别出现肉眼可见便血症状,给药7天后,出现小鼠腹泻症状(包括稀疏粪便)为19%。说明乳双歧杆菌BLa80能显著改善小鼠的腹泻发生率。
实施例9乳双歧杆菌BLa80对小鼠的免疫调节作用
实验取SFP级BALB/c雄性小鼠36只,体重18-20g。动物饲养室温温度23±2℃,湿度50%±10%,12h/12h昼夜交替,自由进食及饮水的条件下适应饲养7天后随机分组,每组12只,分为3组,包括对照组、模型组(DSS)和益生菌+DSS组(灌胃乳双歧杆菌BLa80菌液,同时饮用DSS),试验期14天。对照组,试验开始到结束期间每天自由进食和饮水;模型组,前7天自由进食和饮水,第8天开始在小鼠饮水中添加2.5%(W/V)DSS溶液;益生菌+DSS组:前7天每天灌胃含2.0×109CFU/mL乳双歧杆菌BLa80的PBS溶液0.2mL;从第8天开始,灌胃含2.0×109CFU/mL乳双歧杆菌BLa80的PBS溶液0.2mL,同时小鼠饮水中添加2.5%DSS溶液。实验结束后,摘眼取血引颈处死所有小鼠,取各组小鼠结肠组织,通过ELISA酶联免疫法测定每组小鼠结肠组织匀浆中抗炎因子IL-10、IL-4和促炎因子TNF-α、IL-6的表达量。
结果如图4-7所示:与对照组比,模型组结肠组织中促炎因子TNF-α、IL-6的含量显著升高,抗炎因子IL-4和IL-10的含量显著降低。与模型组比,益生菌+DSS组结肠组织中促炎因子TNF-α、IL-6的含量显著降低,抗炎因子IL-4和IL-10的含量显著升高。与对照组,益生菌+DSS组的抗炎因子IL-4和IL-10的含量差异无显著。实验表明,乳双歧杆菌BLa80能够调节小鼠肠道免疫能力,降低小鼠结肠组织中促炎因子的表达,提高抗炎因子的表达。
上述实施例便于本领域技术人员更好的理解本发明,本发明的实施方式并不受上述实施例的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
Claims (8)
1.一种乳双歧杆菌(Bifidobacterium animalis subsp.lactis)在制备抑菌产品中的应用,其特征在于:所述的乳双歧杆菌为保藏编号为CGMCC No.22547的乳双歧杆菌BLa80,所述的抑菌包括抑制大肠杆菌、沙门氏菌和金黄色葡萄球菌。
2.一种乳双歧杆菌在制备预防和/或缓解腹泻产品中的应用,其特征在于:所述的乳双歧杆菌为保藏编号为CGMCC No.22547的乳双歧杆菌BLa80。
3.一种乳双歧杆菌在制备提升肠道免疫能力产品中的应用,其特征在于:所述的乳双歧杆菌为保藏编号为CGMCC No.22547的乳双歧杆菌BLa80。
4.根据权利要求1-3任一项所述的应用,其特征在于:所述的产品为功能性菌剂、食品、保健品和/或药品。
5.一种抑菌产品,其特征在于:包含保藏编号为CGMCC No.22547的乳双歧杆菌BLa80,所述的抑菌包括抑制大肠杆菌、沙门氏菌和金黄色葡萄球菌。
6.一种预防和/或缓解腹泻的产品,其特征在于:包含保藏编号为CGMCC No.22547的乳双歧杆菌BLa80。
7.一种提升肠道免疫能力的产品,其特征在于:包含保藏编号为CGMCC No.22547的乳双歧杆菌BLa80。
8.根据权利要求5-7任一项所述的产品,其特征在于:所述的产品为功能性菌剂、食品、保健品和/或药品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110978637.8A CN113913322B (zh) | 2021-08-25 | 2021-08-25 | 乳双歧杆菌BLa80在缓解腹泻和提升肠道免疫能力中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110978637.8A CN113913322B (zh) | 2021-08-25 | 2021-08-25 | 乳双歧杆菌BLa80在缓解腹泻和提升肠道免疫能力中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113913322A true CN113913322A (zh) | 2022-01-11 |
CN113913322B CN113913322B (zh) | 2022-11-22 |
Family
ID=79233454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110978637.8A Active CN113913322B (zh) | 2021-08-25 | 2021-08-25 | 乳双歧杆菌BLa80在缓解腹泻和提升肠道免疫能力中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113913322B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110893193A (zh) * | 2019-06-27 | 2020-03-20 | 内蒙古伊利实业集团股份有限公司 | 乳双歧杆菌bl-99的新应用 |
CN114350577A (zh) * | 2022-03-17 | 2022-04-15 | 微康益生菌(苏州)股份有限公司 | 一种改善便秘的动物双歧杆菌乳亚种BLa36及其培养方法与应用 |
CN114480229A (zh) * | 2022-04-15 | 2022-05-13 | 微康益生菌(苏州)股份有限公司 | 一种动物双歧杆菌乳亚种菌株wkb148及其产品与应用 |
CN115518080A (zh) * | 2022-10-20 | 2022-12-27 | 微康益生菌(苏州)股份有限公司 | 乳双歧杆菌BLa80在改善和缓解过敏反应上的应用 |
CN116445356A (zh) * | 2023-04-28 | 2023-07-18 | 微康益生菌(苏州)股份有限公司 | 一种调节肠道菌群及增强免疫力的动物双歧杆菌乳亚种ba67及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105166914A (zh) * | 2015-10-27 | 2015-12-23 | 江西美庐乳业集团有限公司 | 一种能调节肠道微生态环境,提升宝宝抗病能力、改善腹泻的营养包 |
CN110452842A (zh) * | 2019-08-01 | 2019-11-15 | 诺佰克(武汉)生物科技有限公司 | 乳双歧杆菌nbk-W13及其应用 |
CN112870232A (zh) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | 乳双歧杆菌bl-99提升肠道细菌感染抗性和肠道免疫力的应用 |
CN113088465A (zh) * | 2021-04-02 | 2021-07-09 | 湖北均瑶大健康饮品股份有限公司 | 一种乳双歧杆菌Bifidobacterium lactis菌株J605及其应用 |
CN113564078A (zh) * | 2021-07-29 | 2021-10-29 | 微康益生菌(苏州)股份有限公司 | 一株降胆固醇的乳双歧杆菌BLa80及其应用 |
-
2021
- 2021-08-25 CN CN202110978637.8A patent/CN113913322B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105166914A (zh) * | 2015-10-27 | 2015-12-23 | 江西美庐乳业集团有限公司 | 一种能调节肠道微生态环境,提升宝宝抗病能力、改善腹泻的营养包 |
CN110452842A (zh) * | 2019-08-01 | 2019-11-15 | 诺佰克(武汉)生物科技有限公司 | 乳双歧杆菌nbk-W13及其应用 |
CN112870232A (zh) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | 乳双歧杆菌bl-99提升肠道细菌感染抗性和肠道免疫力的应用 |
CN113088465A (zh) * | 2021-04-02 | 2021-07-09 | 湖北均瑶大健康饮品股份有限公司 | 一种乳双歧杆菌Bifidobacterium lactis菌株J605及其应用 |
CN113564078A (zh) * | 2021-07-29 | 2021-10-29 | 微康益生菌(苏州)股份有限公司 | 一株降胆固醇的乳双歧杆菌BLa80及其应用 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110893193A (zh) * | 2019-06-27 | 2020-03-20 | 内蒙古伊利实业集团股份有限公司 | 乳双歧杆菌bl-99的新应用 |
CN110893193B (zh) * | 2019-06-27 | 2023-03-24 | 内蒙古伊利实业集团股份有限公司 | 乳双歧杆菌bl-99的新应用 |
CN114350577A (zh) * | 2022-03-17 | 2022-04-15 | 微康益生菌(苏州)股份有限公司 | 一种改善便秘的动物双歧杆菌乳亚种BLa36及其培养方法与应用 |
CN114350577B (zh) * | 2022-03-17 | 2022-05-27 | 微康益生菌(苏州)股份有限公司 | 一种改善便秘的动物双歧杆菌乳亚种BLa36及其培养方法与应用 |
CN114480229A (zh) * | 2022-04-15 | 2022-05-13 | 微康益生菌(苏州)股份有限公司 | 一种动物双歧杆菌乳亚种菌株wkb148及其产品与应用 |
CN114480229B (zh) * | 2022-04-15 | 2022-08-09 | 微康益生菌(苏州)股份有限公司 | 一种动物双歧杆菌乳亚种菌株wkb148及其产品与应用 |
CN115518080A (zh) * | 2022-10-20 | 2022-12-27 | 微康益生菌(苏州)股份有限公司 | 乳双歧杆菌BLa80在改善和缓解过敏反应上的应用 |
CN116445356A (zh) * | 2023-04-28 | 2023-07-18 | 微康益生菌(苏州)股份有限公司 | 一种调节肠道菌群及增强免疫力的动物双歧杆菌乳亚种ba67及其应用 |
CN116445356B (zh) * | 2023-04-28 | 2024-01-30 | 微康益生菌(苏州)股份有限公司 | 一种调节肠道菌群及增强免疫力的动物双歧杆菌乳亚种ba67及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN113913322B (zh) | 2022-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111484957B (zh) | 动物双歧杆菌乳亚种i797、其分离纯化方法及应用 | |
CN113913322B (zh) | 乳双歧杆菌BLa80在缓解腹泻和提升肠道免疫能力中的应用 | |
CN113088465B (zh) | 一种乳双歧杆菌Bifidobacterium lactis菌株J605及其应用 | |
WO2022057741A1 (zh) | 动物双歧杆菌及其选育方法和应用 | |
WO2022110727A1 (zh) | 副干酪乳杆菌et-22提升肠道细菌感染抗性和肠道免疫力的应用 | |
CN114480229B (zh) | 一种动物双歧杆菌乳亚种菌株wkb148及其产品与应用 | |
CN114009784B (zh) | 一种耐酸耐胆汁盐定植能力强的益生菌组合物及其制备方法和应用 | |
CN112869167A (zh) | 副干酪乳杆菌k56提升肠道细菌感染抗性和肠道免疫力的应用 | |
CN112812999B (zh) | 一株对阴沟肠杆菌具有抑制作用的植物乳杆菌slb01及其衍生产品和应用 | |
CN114292781B (zh) | 一种长双歧杆菌sysu-02及其应用 | |
CN111566200A (zh) | 对乙醇和乙醛具有降解功能的微生物,包括所述微生物的组合物和试剂盒 | |
CN115851504A (zh) | 益生菌、组合物及其应用 | |
CN111543640A (zh) | 一种具有改善小儿腹泻和消化不良的动物双歧杆菌乳亚种i797的应用 | |
CN111254087B (zh) | 一株具有增强免疫力功能的高黏附性能瑞士乳杆菌及其应用 | |
CN113337440A (zh) | 一株唾液乳杆菌mg-587及其应用 | |
KR100240687B1 (ko) | 락토바실러스 애시도필러스 ky 2104 및 그 용도 | |
CN114990030B (zh) | 嗜酸乳杆菌la18及其在制备调节肠道菌群或免疫调节的产品方面的应用 | |
CN116445356A (zh) | 一种调节肠道菌群及增强免疫力的动物双歧杆菌乳亚种ba67及其应用 | |
CN110106113A (zh) | 一株高加索酸奶乳杆菌msr101及其应用 | |
CN113913334B (zh) | 一株粪肠球菌ef-za1107-06及其应用 | |
CN114806953A (zh) | 一种具有改善1型糖尿病特性的格氏乳杆菌 | |
TW202325835A (zh) | 使用乳酸菌菌株組合來提升腸胃道屏障功能 | |
CN113508907A (zh) | 一株耐热型发酵乳杆菌在制备促排便食品或药品中的应用 | |
CN117448243B (zh) | 一株具有益生功能且能增强免疫的嗜粘蛋白阿克曼氏菌Akk007及其应用与保健品 | |
CN117070398B (zh) | 一种改善便秘的动物双歧杆菌乳亚种Bi66及其应用、产品和方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |